Literature DB >> 30051533

Low-grade neuroepithelial tumor: Unusual presentation in an adult without history of seizures.

Giulio Riva1, Luca Cima1, Manuela Villanova1, Claudio Ghimenton1, Sokol Sina1, Luca Riccioni2, Giada Munari3, Matteo Fassan3, Felice Giangaspero4,5, Albino Eccher1.   

Abstract

Low-grade neuroepithelial tumors (LGNT) show a broad histopathological spectrum and may be difficult to classify using current World Health Organization (WHO) criteria. A 57-year-old man came to medical attention because of headaches. The patient medical history was otherwise unremarkable. Magnetic resonance imaging (MRI) revealed a 2.5 cm lesion, partially cystic, with an increased signal on T2-weighted imaging, located in the right frontal lobe. The patient underwent right frontal craniotomy and the surgical specimen was entirely evaluated. Microscopic examination showed a tumor arranged predominantly in sheets and nests, with an infiltrative growth pattern and oligodendroglioma-like appearance. Tumor cells were round to oval with cytoplasmic clearing, hyperchromatic nuclei and inconspicuous nucleoli. Only one mitosis was identified. Necrosis was absent. Differential diagnostic considerations included oligodendroglioma, clear cell ependymoma, polymorphous low-grade neuroepithelial tumor of the young (PLNTY) and long-term epilepsy-associated tumor with clear cell morphology. Neoplastic cells showed positivity for glial fibrillary acidic protein (GFAP), oligodendrocyte transcription factor 2 (OLIG2), α-thalasemia X-linked mental retardation syndrome (ATRX) (retained nuclear expression) and CD34. Epithelial membrane antigen (EMA), neuronal nuclear antigen, microtubule-associated protein-2e, cyclo-oxygenase-2, chromogranin A and isocitrate dehydrogenase 1 (IDH1) (R132H) were negative. Ki-67 labeling index was 2-3%. Molecular analysis identified neither IDH1/IDH2 mutations nor 1p19q codeletion. Rapidly accelerated fibrosarcoma homolog B1 (BRAF) V600E mutation was also absent by both molecular and immunohistochemical testing. Polymerase chain reaction analysis revealed the presence of fibroblast growth factor receptor 3 (FGFR3)-transforming acidic coiled-coil (TACC) fusion. Taken together, the morphological, immunohistochemical and molecular findings supported the final diagnosis of PLNTY.
© 2018 Japanese Society of Neuropathology.

Entities:  

Keywords:  CD34; FGFR3-TACC3 fusion; PLNTY; brain tumors; low-grade neuroepithelial tumor

Mesh:

Year:  2018        PMID: 30051533     DOI: 10.1111/neup.12504

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  11 in total

1.  Neuroradiological features of the polymorphous low-grade neuroepithelial tumor of the young: five new cases with a systematic review of the literature.

Authors:  Mariko Kurokawa; Ryo Kurokawa; Aristides A Capizzano; Akira Baba; Yoshiaki Ota; Emile Pinarbasi; Timothy Johnson; Ashok Srinivasan; Toshio Moritani
Journal:  Neuroradiology       Date:  2022-01-10       Impact factor: 2.804

Review 2.  Polymorphous Low-Grade Neuroepithelial Tumor of the Young as a Partially Calcified Intra-Axial Mass in an Adult.

Authors:  J C Benson; D Summerfield; C Carr; P Cogswell; S Messina; J V Gompel; K Welker
Journal:  AJNR Am J Neuroradiol       Date:  2020-03-26       Impact factor: 3.825

3.  FGFR3 overexpression is a useful detection tool for FGFR3 fusions and sequence variations in glioma.

Authors:  Jens Schittenhelm; Lukas Ziegler; Jan Sperveslage; Michel Mittelbronn; David Capper; Isabel Burghardt; Antti Poso; Saskia Biskup; Marco Skardelly; Ghazaleh Tabatabai
Journal:  Neurooncol Pract       Date:  2020-11-20

4.  Coexisting FGFR3 p.K650T mutation in two FGFR3-TACC3 fusion glioma cases.

Authors:  Leomar Y Ballester; Soheil Zorofchian Moghadamtousi; Norman E Leeds; Jason T Huse; Gregory N Fuller
Journal:  Acta Neuropathol Commun       Date:  2019-04-29       Impact factor: 7.801

5.  A "polymorphous low-grade neuroepithelial tumor of the young (PLNTY)" diagnosed in an adult. Report of a case and review of the literature.

Authors:  Giuseppe Broggi; Francesco Certo; Roberto Altieri; Rosario Caltabiano; Marco Gessi; Giuseppe Maria Vincenzo Barbagallo
Journal:  Surg Neurol Int       Date:  2021-09-20

6.  Clinical, Radiological, Pathological Features and Seizure Outcome With Surgical Management of Polymorphous Low-Grade Neuroepithelial Tumor of the Young Associated With Epilepsy.

Authors:  Xiaorui Fei; Jing Zhao; Wei Wei; Wei Wang; Xue Kong; Ruobing Qian; Chaoshi Niu; Yang Yao
Journal:  Front Oncol       Date:  2022-03-18       Impact factor: 6.244

7.  Polymorphous low-grade neuroepithelial tumor of the young: Rare tumor and review of the literature.

Authors:  Ali H Palejwala; Christen M O'Neal; Michael R Quinton; James D Battiste; Jo Elle G Peterson; Ian F Dunn
Journal:  Rare Tumors       Date:  2022-03-28

8.  Polymorphous Low-Grade Neuroepithelial Tumor of the Young (PLNTY): Molecular Profiling Confirms Frequent MAPK Pathway Activation.

Authors:  Cristiane M Ida; Derek R Johnson; Asha A Nair; Jaime Davila; Thomas M Kollmeyer; Kay Minn; Numrah M Fadra; Jessica R Balcom; Kar-Ming A Fung; Dong Kun Kim; Timothy J Kaufmann; Benjamin R Kipp; Kevin C Halling; Robert B Jenkins; Caterina Giannini
Journal:  J Neuropathol Exp Neurol       Date:  2021-09-27       Impact factor: 3.685

9.  BRAF V600E mutation mediates FDG-methionine uptake mismatch in polymorphous low-grade neuroepithelial tumor of the young.

Authors:  Kensuke Tateishi; Naoki Ikegaya; Naoko Udaka; Jo Sasame; Takahiro Hayashi; Yohei Miyake; Tetsuhiko Okabe; Ryogo Minamimoto; Hidetoshi Murata; Daisuke Utsunomiya; Shoji Yamanaka; Tetsuya Yamamoto
Journal:  Acta Neuropathol Commun       Date:  2020-08-18       Impact factor: 7.801

Review 10.  FGFR- gene family alterations in low-grade neuroepithelial tumors.

Authors:  Tejus A Bale
Journal:  Acta Neuropathol Commun       Date:  2020-02-21       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.